Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Current Deferred Revenue for 3 consecutive years, with $8.2 million as the latest value for Q4 2023.

  • Quarterly Current Deferred Revenue fell 76.52% to $8.2 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2023, down 76.52% year-over-year, with the annual reading at $8.2 million for FY2023, 76.52% down from the prior year.
  • Current Deferred Revenue for Q4 2023 was $8.2 million at Actinium Pharmaceuticals, down from $35.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $35.0 million in Q2 2022, with the low at $100000.0 in Q1 2022.
  • Average Current Deferred Revenue over 3 years is $16.6 million, with a median of $8.2 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 34900.0% in 2023, while the deepest fall reached 99.71% in 2023.
  • Over 3 years, Current Deferred Revenue stood at $1.0 million in 2021, then skyrocketed by 3400.0% to $35.0 million in 2022, then tumbled by 76.52% to $8.2 million in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $8.2 million, $35.0 million, and $100000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.